Despite Lack Of New Treatment Options, Network Approach Improves Outcomes In Crohn's Disease And Ulcerative Colitis
Many children with Crohn's disease and ulcerative colitis who received treatment through ImproveCareNow, a national quality improvement and research network, ceased to have symptoms and no longer needed to take steroids for disease management. These are the findings from a study appearing in Pediatrics that examined the ImproveCareNow network's quality improvement efforts and their impact on outcomes. In this study, the proportion of children with Crohn's disease who were in remission increased from 55 percent to 68 percent, with a similar improvement in ulcerative colitis patients. Crohn's disease and ulcerative colitis, also called inflammatory bowel disease (IBD), are gastrointestinal disorders that lead to intestinal inflammation as a result of an overactive immune reaction. Despite therapeutic advances in the treatment of pediatric IBD, there has been limited improvement in outcomes over the last several decades.
Nanoparticles are everywhere. From cosmetics and clothes, to soda and snacks. But as versatile as they are, nanoparticles also have a downside, say researchers at Binghamton University and Cornell University in a recent paper published in the journal Nature Nanotechnology. These tiny particles, even in low doses, could have a big impact on our long-term health. According to lead author of the article, Gretchen Mahler, assistant professor of bioengineering at Binghamton University, much of the existing research on the safety of nanoparticles has been on the direct health effects. But what Mahler, Michael L. Shuler of Cornell University and a team of researchers really wanted to know was what happens when someone gets constant exposure in small doses - the kind you'd get if you were taken a drug or supplement that included nanoparticles in some form.
The Nutritional Immunology and Molecular Medicine Laboratory (NIMML) research team at Virginia Tech has discovered important new information on the efficacy of conjugated linoleic acid (CLA) in treating Crohn's disease, a form of inflammatory bowel disease (IBD). CLA is a naturally occurring acid found in meat and dairy products known for its anti-cancer and immune modulatory properties. In collaboration with the Division of Gastroenterology and Hepathology at University of North Carolina School of Medicine and the Wake Forest Medical Center, researchers found that Crohn's patients who took supplementary CLA showed noticeable improvement. "In our recent open label study of CLA as a supplement in study subjects with mild to moderate CD there was a marked improvement in disease activity and quality of life in 50% of the subjects.
A leaky gut may be the root of some cancers forming in the rest of the body, a new study published online Feb. 21 in PLoS ONE by Thomas Jefferson University researchers suggests. It appears that the hormone receptor guanylyl cyclase C (GC-C) - a previously identified tumor suppressor that exists in the intestinal tract - plays a key role in strengthening the body's intestinal barrier, which helps separate the gut world from the rest of the body, and possibly keeps cancer at bay. Without the receptor, that barrier weakens. A team led by Scott Waldman, M.D., Ph.D., chair of the Department of Pharmacology and Experimental Therapeutics at Jefferson and director of the Gastrointestinal Cancer Program at Jefferson's Kimmel Cancer Center, discovered in a pre-clinical study that silencing GC-C in mice compromised the integrity of the intestinal barrier.
Five new genetic variants linked to Crohn's disease (a chronic inflammatory disease of the intestines) in Jewish people of Eastern European descent (Ashkenazi Jews), have been identified by a team of researchers from Mount Sinai School of Medicine. These findings will help to better understand why the prevalence of the disease is almost four times greater in Ashkenazi Jews than in other populations. The study, led by Inga Peter, Associate Professor at Mount Sinai School of Medicine, is published in PLoS Genetics. Earlier investigations had discovered 71 genetic mutations of Crohn's disease risk in people of European ancestry. In this study, the researchers used DNA samples from 1, 878 Ashkenazi Jews with the disease, and 4, 469 Jews without Crohn's disease, in order to analyze their genetic make-up.